Proteona opens new laboratory in Singapore 11.05.20221’Proteona Pte. Ltd., a subsidiary of Singleron Biotechnologies, and a leader in single-cell multi-omics analysis, today announced the opening of a new operations facility in Science Park 2, Singapore.The new state-of-the-art laboratory is capable of processing over 1,200 samples annually using Singleron and third-party single-cell technologies. It significantly increases Proteona’s capacity to support customers that desire an outsourced solution for single-cell multi-omic sample processing and machine-learning-based data analysis. “Beyond increasing our capacity, the new space allows us to provide new services based on Singleron’s innovative single-cell technologies, expanding the menu of single-cell analysis methods that our customers can access” said Dr. Jonathan Scolnick, CSO of Proteona and General Manager of Singleron Singapore.The new site will function as the regional headquarters for Singleron in Asia outside China with a focus on servicing customers in Singapore, the surrounding Asia-Pacific region, and in the global pharmaceutical and biotechnology industry. The opening of the new facility will also create new bioscience job opportunities in Singapore for both laboratory and commercial personnel. “Placing the laboratory in Singapore was not a coincidence, but a strategic choice” said Dr. Nan Fang, CEO of Singleron. “Singapore’s strong biomedical ecosystem, coupled with its skilled labor force and location in Asia made it an ideal choice for our new Asian regional headquarters.”Proteona was launched in 2018 by co-founders Dr. Jonathan Scolnick, Dr. Gene Yeo, and Dr. Shawn Hoon and as spin-out of the National University of Singapore and A*STAR. It was acquired by Singleron Biotechnologies, based in Nanjing and Suzhou, China and Cologne, Germany in March of 2022.Check out our latest news and events Learn more 24.11.20 Singleron Partners with TOMY to Expand Single Cell Offerings in Japan Cologne, November 20, 2024 – Singleron Biotechnologies, a leader in single cell analysis solutions, has announced a new distributor partnership with TOMY Digital Biology Co.,… Read more 24.10.28 B2B-RARE: Bench to Bedside – Rapid Diagnosis and Personalized Treatment of Rare Neuromuscular Diseases For the German version of the article, see here. NRW, 28th October 2024 – More than 400 genetically determined neuromuscular diseases (NME) are rare diseases…. Read more 24.10.08 Singleron and Bioscreen Announce Strategic Partnership to Enhance Access to Single Cell Multi-Omics Solutions for India Researchers Cologne, October 8, 2024 – Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor… Read more
24.11.20 Singleron Partners with TOMY to Expand Single Cell Offerings in Japan Cologne, November 20, 2024 – Singleron Biotechnologies, a leader in single cell analysis solutions, has announced a new distributor partnership with TOMY Digital Biology Co.,… Read more
24.10.28 B2B-RARE: Bench to Bedside – Rapid Diagnosis and Personalized Treatment of Rare Neuromuscular Diseases For the German version of the article, see here. NRW, 28th October 2024 – More than 400 genetically determined neuromuscular diseases (NME) are rare diseases…. Read more
24.10.08 Singleron and Bioscreen Announce Strategic Partnership to Enhance Access to Single Cell Multi-Omics Solutions for India Researchers Cologne, October 8, 2024 – Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor… Read more